These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24295734)
1. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2. Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734 [TBL] [Abstract][Full Text] [Related]
2. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446 [TBL] [Abstract][Full Text] [Related]
3. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034 [TBL] [Abstract][Full Text] [Related]
4. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer. Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945 [TBL] [Abstract][Full Text] [Related]
5. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix. Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309 [TBL] [Abstract][Full Text] [Related]
6. Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion. Gaudineau B; Fougère M; Guaddachi F; Lemoine F; de la Grange P; Jauliac S J Cell Sci; 2012 Oct; 125(Pt 19):4475-86. PubMed ID: 22767506 [TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer. Chung IH; Chen CY; Lin YH; Chi HC; Huang YH; Tai PJ; Liao CJ; Tsai CY; Lin SL; Wu MH; Chen CY; Lin KH Oncotarget; 2015 Jun; 6(17):15050-64. PubMed ID: 25940797 [TBL] [Abstract][Full Text] [Related]
8. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797 [TBL] [Abstract][Full Text] [Related]
9. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Fougère M; Gaudineau B; Barbier J; Guaddachi F; Feugeas JP; Auboeuf D; Jauliac S Oncogene; 2010 Apr; 29(15):2292-301. PubMed ID: 20101218 [TBL] [Abstract][Full Text] [Related]
10. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785 [TBL] [Abstract][Full Text] [Related]
11. Lipocalin 2 promotes breast cancer progression. Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579 [TBL] [Abstract][Full Text] [Related]
12. HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer. Hu B; Zhang K; Li S; Li H; Yan Z; Huang L; Wu J; Han X; Jiang W; Mulatibieke T; Zheng L; Wan R; Wang X; Hu G Cancer Lett; 2016 Jul; 376(2):387-98. PubMed ID: 27085461 [TBL] [Abstract][Full Text] [Related]
13. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells. Tung MC; Hsieh SC; Yang SF; Cheng CW; Tsai RT; Wang SC; Huang MH; Hsieh YH Prostate; 2013 Sep; 73(12):1281-90. PubMed ID: 23775308 [TBL] [Abstract][Full Text] [Related]
14. C/EBP ζ targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells. Wang L; Li H; Wang J; Gao W; Lin Y; Jin W; Chang G; Wang R; Li Q; Ma L; Pang T Biochim Biophys Acta; 2011 Oct; 1813(10):1803-13. PubMed ID: 21741997 [TBL] [Abstract][Full Text] [Related]
15. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia. Kobara H; Miyamoto T; Suzuki A; Asaka R; Yamada Y; Ishikawa K; Kikuchi N; Ohira S; Shiozawa T Placenta; 2013 Nov; 34(11):1036-43. PubMed ID: 23972287 [TBL] [Abstract][Full Text] [Related]
16. Hypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway. Wang X; Wang Y; Xiao G; Wang J; Zu L; Hao M; Sun X; Fu Y; Hu G; Wang J Oncotarget; 2016 May; 7(21):30350-64. PubMed ID: 27107418 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma. Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874 [TBL] [Abstract][Full Text] [Related]
18. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner. Mahadevan NR; Rodvold J; Almanza G; Pérez AF; Wheeler MC; Zanetti M BMC Cancer; 2011 Jun; 11():229. PubMed ID: 21649922 [TBL] [Abstract][Full Text] [Related]
19. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer. Guo P; Yang J; Jia D; Moses MA; Auguste DT Theranostics; 2016; 6(1):1-13. PubMed ID: 26722369 [TBL] [Abstract][Full Text] [Related]